With the advent of drugs for lung cancer, such as inhibitors of epidermal growth factor receptor and immune checkpoints in recent years, the prognosis is improving.[3,4] However, it is difficult to completely overcome lung cancer due to secondary mutations of driver genes and the exhaustion of immune cells. Here, EGFR is linked to lung cancer.